Valuation : VERE THER

Market Cap 994M 858M 807M 735M 1.38B 94.35B 1.39B 9.54B 3.71B 47.99B 3.73B 3.65B 159B P/E 2023
-4.47x
P/E 2024 -2.4x
Enterprise Value 540M 466M 438M 399M 750M 51.23B 754M 5.18B 2.02B 26.06B 2.03B 1.98B 86.42B EV / Sales 2023
46,430,598x
EV / Sales 2024 717,743x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
3 years 2.86
Extreme 2.8647
20.12
5 years 2.86
Extreme 2.8647
78
10 years 2.86
Extreme 2.8647
78
Manager TitleAgeSince
President - 25/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
25/07/25 Tender

Chief Technology Officer

538,331 0.6358%
25/07/25 Tender

Chief Administrative Officer

534,066 0.6308%
25/07/25 Tender

Founder

3,397,141 4.0125%

Financials

2023 2024
Net sales 11.76 10.14 9.54 8.69 16.34 1.12K 16.43 112.79 43.9 567.64 44.15 43.19 1.88K 32.33 27.89 26.23 23.9 44.94 3.07K 45.19 310.14 120.71 1.56K 121.39 118.76 5.18K
Net income -200M -173M -162M -148M -278M -18.99B -280M -1.92B -747M -9.66B -751M -735M -32.03B -199M -171M -161M -147M -276M -18.86B -278M -1.91B -742M -9.59B -746M -730M -31.81B
Net Debt -549M -474M -445M -406M -763M -52.11B -767M -5.27B -2.05B -26.51B -2.06B -2.02B -87.89B -454M -392M -369M -336M -632M -43.12B -635M -4.36B -1.7B -21.93B -1.71B -1.67B -72.72B
Logo VERE THER
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.
Employees
274
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. VERV Stock